• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

A Fail-Safe Healthcare Stock for Patient Investors

Biotech Letter

Warren Buffett is arguably one of the most celebrated investing minds in history. In the 57 years that the Oracle of Omaha was hailed as the leader of Berkshire, the business’ Class A shares (BRK.A0 grew 3,641,613% through December 31, 2021.

In fact, his company has been outperforming the broader market by leaps and bounds that even if Berkshire’s shares fall 99% tomorrow, it would still be ahead of the S&P 500—an achievement it has been celebrating since 1965.

While there’s a long list of factors behind Buffett’s long-running success, his preference for relatively safe businesses serves as one of the foundations of Berkshire’s superior and stable returns.

One of the companies in Berkshire’s portfolio is Johnson & Johnson (JNJ). Although it comprises only 0.02% of Buffett’s holdings, JNJ represents the steady and long-term holdings the Oracle has been known to chase.

Since August 2012, the company’s trailing-12-month net profit has climbed by 116%, exceeding $18.3 billion. To hit that mark, JNJ creates and markets a slew of products and treatments alongside medical devices and consumer health staples such as Tylenol and Sudafed.

It’s highly probable that JNJ’s stable track record of growth and success in expanding and diversifying its portfolio year after year is what lured Buffett to invest in the company.

JNJ’s operating segments hold a vital role in its growth as well. Although marketing brand-name pharmaceuticals comprise the majority of JNJ’s operating and growth margins, the reality is that brand-name products can only hold on to a finite period of exclusivity in sales.

To counter the issues involving patent cliffs, JNJ has implemented a myriad of tactics. For instance, it can rely on its top-performing medical device segment to help augment the loss of income.
For JNJ, when one door closes, another door or a group of doors tend to open.

Unlike most businesses that attract Buffett, which have wide economic moats, JNJ’s significant competitive edges rely on its sheer size compared to its rivals and the brand recognition attached to most of its products.

Nevertheless, a considerable part of its lineup speaks volumes in terms of highlighting Buffett’s preference for businesses that allow him to generate income without necessitating additional investments in development.

If you really think about it, you’ve likely purchased Tylenol or Listerine mouthwash several times in your life. The formulas have not been modified or changed that much, and neither has JNJ’s unit economics when it comes to manufacturing them.

Another factor that makes JNJ an excellent company is its continuity in operations. Keep in mind that this company has been in business for 136 years, and within that period, it only had 10 CEOs. Possessing continuity in critical leadership roles has guaranteed that strategic goals are constantly met.

On top of these, JNJ is one of the most financially sound—if not the most economically sound—publicly traded companies in the world. It has boosted its base annual dividend consistently over the past 60 years. It is recognized as one of the only two publicly traded companies with the highest credit rating (AAA) awarded by Standard & Poor.

Moreover, JNJ is a thriving healthcare stock.

Healthcare stocks are one of the most stable investments since they are defensive. Regardless of the economy and stock market performance, people will continue to buy prescription medicine, use medical devices, and avail of healthcare services. Therefore, this puts minimal demand on healthcare stocks. We do not stop getting sick or going to hospitals because Wall Street hits a roadblock.

Overall, JNJ is an excellent, safe, and reliable long-term investment. While it has not outperformed the broader market in the past 10 years, the business brings joy to its shareholders by steadily paying and boosting its dividend.

There’s a catch here, though. Buying a stock like JNJ signifies your willingness to hold it for years. Hence, this is a business for patient investors only.

 

jnj buffett

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-08-16 17:00:492022-08-27 02:16:43A Fail-Safe Healthcare Stock for Patient Investors
You might also like
September 24, 2020
March 15, 2019
From an Unknown mRNA Pioneer to Big Pharma Player
The Market Outlook for the Week Ahead, or Wake Up Call
Cashing In On Cures
The Stock That Keeps on Giving

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: August 16, 2022 Link to: August 16, 2022 August 16, 2022 Link to: August 16, 2022 Link to: August 16, 2022 August 16, 2022
Scroll to top